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Summary
Introduction—Pulmonary embolism (PE) is a leading cause of mortality in hospitalized patients,
yet the prevalence of PE in sickle cell disease (SCD) and its relation to disease severity or intrinsic
hypercoagulability are not established.
Methods—We estimated inpatient PE incidence and prevalence among SCD and non-SCD
populations in Pennsylvania, and compared severity of illness and mortality, using Pennsylvania
Health Care Cost Containment Council (PHC4) discharge data, 2001-2006. Risk factors for PE
were assessed in a case-control study of discharges from the University of Pittsburgh Medical
Archival Records System (MARS).
Results—The incidence of inpatient PE was higher in the SCD PA population than in the non-
SCD Pennsylvania population, 2001-2006. The PE prevalence among SCD discharges ≤50 years
of age, 0.57%, was similar to that in non-SCD Pennsylvania discharges, 0.60%, and unchanged
after adjustment for race. Among SCD discharges, those developing PE were significantly older,
with longer length ofstay, greater severity of illness, and higher mortality, p<0.001, than SCD
without PE. Among PE discharges, SCD had similar severity of illness, p=0.77, and mortality,
p=0.39, but underwent fewer computerized tomographic scans, p=0.006, than non-SCD with PE.
In the local case-control study, no clinical or laboratory feature was associated with PE.
Conclusions—The incidence of PE is higher and chest CT utilization is lower in SCD than non-
SCD inpatients, suggesting that PE may be under-diagnosed.
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Introduction
Although thrombosis has been recognized as a complication of sickle cell trait [1], and
coagulation and platelet activation are present even in the non-crisis state [2], the rates of
thrombosis are not established in sickle cell disease (SCD). In a study of hospitalized SCD
patients, the prevalence of pulmonary embolism (PE) was 3.5 fold higher than in age-
matched non-SCD African Americans, although the prevalence of deep venous thrombosis
(DVT) was not increased [3]. Thrombosis is an important clinical issue in SCD, as it may be
driven not only by coagulation and platelet activation, but also by hemolysis-associated
endothelial dysfunction [2, 4-6]. Pulmonary emboli may contribute to pulmonary symptoms
associated with acute chest syndrome and pulmonary hypertension [7], and while identified
in up to 50% of autopsied SCD cases [8, 9], are detected clinically in only 5% of cases
[10-12], in part because they are difficult to distinguish from in situ thrombosis [12, 13].
Further, although PE are not thought to cause acute chest syndrome [14], they are
considered a leading cause of death in those with acute chest syndrome [7-12, 15].
Pulmonary artery thrombosis has also been detected in up to 17% of those hospitalized with
acute chest syndrome (ACS), particularly in those with higher platelet counts [16],
suggesting that PE in SCD may actually represent thrombi formed in the pulmonary arteries
rather than embolic events from distal venous circulation. Despite these findings, the role of
anticoagulation in SCD is not established. Among hospitalized patients, PE accounts for
10% of deaths [7], for which prophylactic anticoagulation guidelines have been
recommended [17], yet the impact of anticoagulation on health outcomes in SCD patients,
who are frequently hospitalized, has not been thoroughly studied, and prophylactic
anticoagulation is not routinely prescribed in hospitalized SCD patients. Small clinical trials
have demonstrated benefit of anticoagulation on painful crisis and pain scores [18-22], but
few data address the impact of anticoagulation on thrombosis prevention. We determined the
incidence and prevalence of pulmonary embolism by analyzing Pennsylvania state inpatient
discharge data (2001-2006) by age, gender, race, diagnostic procedures, and severity of
illness, comparing SCD patients developing PE, SCD patients not developing PE, and non-
SCD patients developing PE.
Materials and Methods
Inpatient hospital discharge data for pulmonary embolism for the most recent 5-year period
available, 2001-2006, were obtained from the Pennsylvania Health Care Cost containment
Council (PHC4). The PHC4 is an independent agency that collects inpatient hospital
discharge and ambulatory/ outpatient procedure records from hospitals and ambulatory
surgery centers in Pennsylvania to assess health care costs [23]. We compared age, race and
sex, co-morbidity, procedures, mortality, and Atlas severity of illness in SCD discharges
with and without PE and non-SCD discharges without PE by analyzing PHC4 statewide
discharge data between 2001 and 2006. All patient identifiers were removed. SCD was
defined by ICD-9 codes for HbSS, HbSC, HbS/thal, and HbAS (sickle trait) (codes 282.60;
282.61; 282.62; 282.63; 282.64; 282.68; and 282.69) [24]. PE discharges were identified
using ICD-9 codes 512.11 and 415.19. Pregnant patients and all second or later admissions
for PE were excluded from analysis. Pennsylvania population figures were obtained from
the U.S. Census Bureau [25]. Estimates of Pennsylvania adults affected by SCD were based
on Pennsylvania state department of health data [26], U.S. state-specific SCD prevalence
data [27], and physician estimates [28]. Diagnostic procedures were identified using revenue
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codes for CT (including spiral CT) scans. Clinical data, including height, weight, type of
crisis, severity of crisis based on hemoglobin, reticulocytes, white blood cells, platelets, and
HbF were analyzed. Co-morbidities were also collected, including trauma and congestive
heart failure.
Data not available in the PHC4 database, including co-morbidities, medications, red blood
cell transfusions, laboratory measures, and pain crises, were obtained on all available SCD
with PE and SCD without PE inpatients at University of Pittsburgh Medical Center (UPMC)
during the same time period, using the same ICD-9 codes, from the Medical Archival
Record System (MARS) database, by an honest broker. Co-morbidities included pneumonia,
stroke, acute coronary syndrome, and fractures; and confounders included hypertension,
smoking, hypercholesterolemia, diabetes, HIV infection, and body mass index (BMI).
Procedures included all computerized tomographic (CT) scans, spiral CT scans, chest
roentgenograms (CXR), arterial blood gases (ABG), electrocardiograms (EKG),
echocardiograms (ECHO); and laboratory findings included hemoglobin, reticulocytes,
white blood cells, platelets, and d-dimer assay. Specific medications included hydroxyurea,
iron chelating agents, anticoagulation agents including enoxaparin, warfarin, and
unfractionated heparin. Subset SCD patients with PE (cases) were matched to SCD patients
without PE (controls) in the MARS system by age within five years, race, gender, and year
of admission. For the local dataset (MARS database), all SCD cases with PE were verified
independently by E.M.N., the physician caring for the patients. The CT and V/Q scans of
these patients were also independently verified for each of the local SCD with PE and SCD
without PE patients to verify any PE diagnoses that had not been previously coded: none
were detected.
Data from categorical variables were analyzed using frequencies and percentages to describe
the distributions of the variables for all SCD patients and by PE status. Percentages were
compared across groups by SCD and PE status by chi-square and Fisher's exact test. Data
from continuous measures were summarized using, means and standard deviations, and
comparisons were by two-sample Student's t-test.
Results
The PE incidence between 2001 and 2006 was 50-100-fold higher in the SCD population
than in the general Pennsylvania population (Table 1). SCD PE incidence is based on the
total number of SCD patients in PA, which is an estimate, although with good agreement
among cited sources [26-28]. By contrast, the prevalence of PE among SCD admissions over
the period, 0.57%, was similar to the proportion of PE among non-SCD PE admissions,
0.60%, increasing about 1.5-fold over the period in both the SCD and non-SCD groups,
0.51% to 0.72%, and from 0.49% to 0.72%, respectively (Table 1). SCD PE prevalence is
based on the annual rate of SCD admissions, and, thus, may reflect the higher annual rate of
SCD than non-SCD admissions. The prevalence of PE among African-American SCD
admissions over the period, 0.58%, was similar to the prevalence of PE among African-
American non-SCD admissions, 0.59%.
Compared with non-SCD admissions with PE ≤50 years of age, SCD admissions with PE
had similar Atlas severity of illness scores, 8.1% vs. 7.7% in the two highest categories,
p=0.77, and mortality, 6.2% vs. 4.2%, p=0.39, but underwent fewer CT scans, 42.0% vs.
57.2%, p=0.006 (Table 2). Comparing to inpatient African-Americans only, the rate of CT
scans was similar,42.0% vs. 46.0%, p=0.48. SCD admissions with PE were older, 37.0 vs.
28.0 years, p<0.0001, had a longer length of stay, 9.2 vs. 5.0 days, p<0.0001, greater Atlas
severity of illness, 8.1% vs. 3.3% in the two highest categories, p<0.0001, and higher
inpatient mortality, 6.2% vs. 1.4%, p=0.0006, than SCD admissions without PE. Further,
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SCD admission with PE were more likely to undergo imaging studies, including CT scan,
42.0% vs. 9.6%, p=0.0001, than SCD without PE (Table 2).
Analysis of a local University of Pittsburgh sample revealed no distinguishing clinical
features associated with PE (Table 3). The data confirmed the longer length of stay and
greater use of CT scans among hospitalized SCD with PE as compared with hospitalized
SCD without PE. Comorbidities were no greater in cases than controls, nor were risk factors
for thrombosis, including diabetes, hypertension, obesity, smoking, hyperlipidemia,
coronary symptoms, HIV, or HCV. There were also no differences in the sickle cell
genotype, i.e. HbSS, HbSC, HbS/thal, or HbAS (sickle trait), p=0.861, type of crisis,
p=0.895, laboratory parameters, transfusions, or iron chelation therapy. As expected, all of
those SCD with PE received anticoagulation, but only 15% of hospitalized SCD without PE
did, p<0.001.
Discussion
Utilizing a large discharge database from the state of Pennsylvania, this study establishes the
higher incidence of PE in individuals with SCD than in non-SCD individuals on a year-by-
year basis. PE prevalence among hospitalized SCD patients was comparable to non-SCD
patients, even after adjusting for age and race. There was similar severity of illness and
mortality, but proportionately fewer CT scans were performed in SCD discharges with PE
than non-SCD discharges with PE.
Pulmonary embolism may go unrecognized in SCD patients, including in 17% of acute chest
syndrome (ACS) who develop PE [16] and in up to 90% who die of PE [29]. Given the 6%
mortality rate we found among SCD with PE, which is at least 4-fold greater than that
among SCD without PE, and the evolving refinement of chest CT technology with potential
for earlier PE detection [23], consideration should be given to a higher index of suspicion
and a lower threshold for performing chest CT pulmonary angiography [30] in SCD
patients, particularly in those with pulmonary symptoms. Prospective clinical studies will be
needed to confirm the utility of this approach.
Although all SCD with PE subjects received anticoagulation, fewer than 15% of hospitalized
SCD without PE received anticoagulation. The latter is consistent with published VTE
prophylaxis practices in this group [31, 32] and consistent with Chest 2012
recommendations for anticoagulant thromboprophylaxis in hospitalized patients at increased
risk of thrombosis who are not bleeding or at high risk for bleeding [33]. While
anticoagulation trials in SCD patients have shown variable results [18-22], SCD-related
rather than thrombosis-related outcomes were assessed, and, thus, whether anticoagulation is
safe in SCD remains unanswered. However, the absence of bleeding or hematologic
differences between groups suggests there may be no increased risk. In the absence of clear
contraindication to VTE prophylaxis, and given our finding that PE prevalence is at least as
common in hospitalized SCD as in hospitalized non-SCD patients, prophylactic
anticoagulation should be considered in all SCD inpatients, and clinical trials initiated to
determine the safety and efficacy of prophylactic anticoagulation in hospitalized SCD
patients.
No distinguishing clinical or laboratory parameter was found to be predictive of PE in this
study. This may relate to the small sample of subjects in our MARS system, suggesting the
need for prospective studies with more accurate VTE detection, e.g. via CT pulmonary
angiography, and with better VTE prediction biomarkers, e.g. rate of hemolysis, von
Willebrand factor levels, platelet activation, and cytokines [2, 29, 31, 32].
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There are a number of limitations of this study. First, the incidence of PE in SCD patients in
Pennsylvania is likely to be an underestimate as only hospitalized Pennsylvania patients are
included, excluding non-Pennsylvania residents, Pennsylvania residents admitted in other
states, or those who die before admission. Further, chest CT appears to be under-utilized in
SCD patients, whose signs and symptoms may mimic PE. Second, the power of the case-
control study to identify predictors of PE among SCD patients may be limited by the small
number of local subjects with SCD identified in the MARS database. Third, there is the
possibility of ascertainment bias, that is, SCD patients who present with a primary diagnosis
of sickle cell crisis may not have been coded with a second diagnosis of PE, a potential
limitation of using ICD-9 codes to identify patients for inclusion in this study. It should be
noted, however, that all local cases were independently verified by their physician, E.M.N.,
and independent review of all pulmonary tomographic scans revealed that no cases were
incorrectly identified. Fourth, it was not possible to determine the cause of PE in this study,
as the PHC4 database does not distinguish whether PE was the admitting diagnosis or
subsequent diagnosis. Finally, although a diagnosis of sickle trait was included within the
study definition for SCD, it should be noted that many with sickle trait may be unaware of
their status, and, thus these data could lead to erroneous conclusions about its role as a
possible risk factor for PE.
Despite these limitations, the study has some major strengths. The use of Pennsylvania
discharge data and US census population data for the state provided the opportunity to
determine the incidence of PE in hospitalized SCD and to demonstrate that PE prevalence is
similar between hospitalized SCD and non-SCD patients. The fact that proportionately
fewer SCD undergo diagnostic CT scans and only a minority receives prophylactic
anticoagulation suggests the need for heightened suspicion, earlier detection, and clinical
trials to determine whether prophylactic anticoagulation in hospitalized SCD patients is
warranted.
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